Liquidia Co. (NASDAQ:LQDA) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in Liquidia Co. (NASDAQ:LQDA) by 855.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 235,393 shares of the company’s stock after purchasing an additional 210,753 shares during the quarter. JPMorgan Chase & Co.’s holdings in Liquidia were worth $2,354,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Whitefort Capital Management LP boosted its stake in shares of Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after purchasing an additional 230,820 shares during the period. HighVista Strategies LLC boosted its stake in shares of Liquidia by 48.6% in the third quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock valued at $1,809,000 after purchasing an additional 59,193 shares during the period. Wellington Management Group LLP boosted its stake in shares of Liquidia by 12.5% in the third quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock valued at $1,799,000 after purchasing an additional 19,932 shares during the period. Finally, Anson Funds Management LP purchased a new position in shares of Liquidia in the third quarter valued at approximately $1,764,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the transaction, the insider now owns 270,388 shares of the company’s stock, valued at $3,185,170.64. This represents a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,055 shares of company stock worth $836,299. Corporate insiders own 30.10% of the company’s stock.

Liquidia Stock Up 5.7 %

Liquidia stock opened at $13.62 on Wednesday. The firm has a market capitalization of $1.15 billion, a PE ratio of -8.36 and a beta of 0.23. The firm’s 50-day simple moving average is $11.34 and its 200 day simple moving average is $11.03. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.99.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LQDA shares. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank started coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Lifesci Capital started coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Wells Fargo & Company started coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Liquidia has an average rating of “Buy” and an average price target of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).